Emtricitabine/Tenofovir disoproxil phosphate

恩曲他滨/磷酸替诺福韦二吡呋酯

Report date: 2022/12/07 18:09:28
NME

Base Information

Drug NameEmtricitabine/Tenofovir disoproxil phosphate
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEU
CombinationsYes EmtricitabineTenofovir disoproxil phosphate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR03
Related LinksN/A